Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Business & Industry
- Bayer launches LifeHub UK focused on artificial intelligence to optimize data-driven drug discovery and disease diagnosis
- Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
- The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
- Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
- Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
Research & Development
- First entirely digital clinical trial encourages physical activity
- New strategy to treat Parkinson's disease
- AI could offer warnings about serious side effects of drug-drug interactions
- Antibody-based eye drops show promise for treating dry eye disease
- Powerful new genomics method can be used to reveal the causes of rare genetic diseases
- AI and big data predict which research will influence future medical treatments
- Pharmacists provide patient value in team-based care
Conferences & Events
- 'FDA should withdraw ANDAs', and 'new technologies could bring massive improvements in efficiency' if implemented correctly
- SMi's 9th Annual Orphan Drugs & Rare Diseases Conference
- SMi's Inaugural Pharmaceutical Manufacturing & Cleanroom Technology Conference
- Disruptive Technologies in Pharma 2019
- Respiratory Drug Delivery 2019
- Exclusive iVeena speaker interview released for 3rd Ophthalmic Drugs Conference
- eyeforpharma The Marketing Disruption Summit
Regulatory Affairs
- FDA approves new treatment for patients with migraine
- FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
- FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
- FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity
- FDA approves first oral GLP-1 treatment for type 2 diabetes